Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892341 | 0.90 | MEN1 (0.49) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027964 | 0.89 | MEN1 (0.62) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891935 | 0.88 | MEN1 (0.50) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027981 | 0.87 | MEN1 (0.60) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3338056 | 0.87 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027957 | 0.87 | MEN1 (0.60) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027955 | 0.87 | MEN1 (0.59) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027962 | 0.85 | MEN1 (0.68) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027731 | 0.85 | MEN1 (0.71) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2893359 | 0.85 | KMT2A (0.60) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445915-B1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2542553-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF 4-OXO-3,4-DIHYDRO-IMIDAZO[5,1-D][1,2,3,5]TETRAZINES | Pharminox Ltd (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-2445915-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | Pharminox Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| WO-2011107726-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF 4-OXO-3,4-DIHYDRO-IMIDAZO[5,1-D][1,2,3,5]TETRAZINES | PHARMINOX LTD (GB) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107726-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF 4-OXO-3,4-DIHYDRO-IMIDAZO[5,1-D][1,2,3,5]TETRAZINES | PHARMINOX LTD (GB) | 2011-09-09 | — | — | WO | disclosed |
| WO-2010149968-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | MKI67, CCNA1, CCNI | MEN1 937/4885PABPC1 3125/4885KMT2A 584/4885 |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA6, TALDO1 | MEN1 216/4885PABPC1 4575/4885KMT2A 327/4885 |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | MKI67, CCNI, CDK4 | MEN1 3049/4885PABPC1 3755/4885KMT2A 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.